Vraylar, cariprazine
Named-patient access overview. Vraylar is coordinated by Reserve Meds for international patients via physician-led cross-border sourcing.
This page is informational, not medical advice.
About Vraylar
Vraylar (cariprazine) is an oral atypical antipsychotic developed by Gedeon Richter and commercialised in the United States by AbbVie (originally Allergan). The US Food and Drug Administration first approved cariprazine in 2015 for schizophrenia and manic or mixed episodes associated with bipolar I disorder. The label expanded in 2019 to include depressive episodes of bipolar I and again in 2022 to include adjunctive treatment of major depressive disorder in adults who have an inadequate response to antidepressant therapy alone. Vraylar is taken once daily as an oral capsule in strengths from 1.5 mg through 6 mg.
Pharmacologically, cariprazine is a partial agonist at dopamine D3 and D2 receptors with notable preference for D3, together with partial agonism at serotonin 5-HT1A and antagonism at 5-HT2A and 5-HT2B receptors. Its long half-life and active metabolites give it a distinctive pharmacokinetic profile compared with other atypical antipsychotics, which prescribing psychiatrists factor into titration and assessment of clinical response.
For international patients, Vraylar's local registration status varies widely. In some Reserve Meds markets cariprazine is available under a different brand from Gedeon Richter; in others it is not registered at all. Patients sometimes pursue the US-branded Vraylar via named-patient or personal-import pathways when their treating psychiatrist has chosen this specific molecule and local supply is unavailable or interrupted. Reserve Meds coordinates that sourcing from DSCSA-compliant US specialty channels.
How Reserve Meds coordinates Vraylar
- Patient or treating physician submits a named-patient request through our intake.
- The clinical team reviews appropriateness of Vraylar for the patient's indication, prior therapies, and destination country.
- The treating psychiatrist issues a prescription and a written clinical justification.
- Country-specific named-patient or personal-import documentation is prepared.
- Vraylar is sourced from a DSCSA-compliant US specialty wholesaler with full serial-number traceability.
- The shipment is coordinated to the patient's physician, pharmacy, or home address, depending on the country pathway.
A single concierge coordinator stays with the case from intake through delivery. The coordinator owns documentation, timeline, customs, and confirmation of receipt.
Access by country
Reserve Meds publishes a detailed country deep-dive for Vraylar in every market we coordinate. Each page below covers the destination-country regulatory pathway, real costs in local currency and USD, indicative timelines, physician-credential requirements, and cold-chain handling. Tap any country to read the full deep-dive.
What patients typically ask about Vraylar
What conditions is Vraylar approved for? In the US label, Vraylar is approved for schizophrenia in adults, acute manic or mixed episodes of bipolar I disorder, depressive episodes of bipolar I disorder, and adjunctive therapy for major depressive disorder in adults with an inadequate response to antidepressants. The treating psychiatrist will discuss which of these applies to a given patient.
How is Vraylar different from other atypical antipsychotics? Its preference for the dopamine D3 receptor and its long half-life are commonly cited differences. The clinical implication is that titration and assessment of response unfold over weeks rather than days. Tolerability profile, including risk of akathisia and metabolic effects, is also a topic for the prescribing psychiatrist.
Is Vraylar registered in my country? In several Reserve Meds markets, cariprazine is available locally under a Gedeon Richter brand. In other markets it is not registered. The country deep-dives linked above explain whether the local brand is available, whether the US Vraylar must be imported via named-patient pathways, and the documentation in each case.
How is Vraylar shipped? Vraylar is an oral capsule at ambient temperature, so cold-chain handling is not required. Standard international logistics with documentation review apply.
What does a course cost? Patients pay for the medicine plus Reserve Meds coordination, regulatory documentation, and shipping. Costs vary by destination because of duties, VAT, and country-specific documentation. The per-country deep-dives publish indicative ranges; firm quotes are issued after intake.
Clinical and safety notes
Vraylar carries the class boxed warning for atypical antipsychotics, including increased mortality in elderly patients with dementia-related psychosis and an increased risk of suicidal thoughts and behaviours in children, adolescents, and young adults taking antidepressants. The treating psychiatrist will discuss the full risk profile. Common adverse reactions include extrapyramidal symptoms, akathisia, dyspepsia, vomiting, somnolence, and restlessness. Drug-interaction considerations include strong CYP3A4 inhibitors and inducers.
Reserve Meds does not replace the prescribing relationship. We coordinate access to a US-licensed medicine for a patient already under physician care. Patients who experience worsening mood, suicidal thoughts, neuromuscular symptoms, or any concerning side effect should contact their treating psychiatrist promptly. Reserve Meds is not an emergency service.
How Vraylar fits a psychiatric treatment plan
Across schizophrenia, bipolar I disorder, and adjunctive treatment of major depressive disorder, Vraylar is one option among several second-generation antipsychotics that a treating psychiatrist may consider. The choice among them turns on several factors: prior response and tolerability, side-effect priorities (metabolic burden, sedation, akathisia, prolactin effects, weight changes), drug-interaction profile, dosing regimen, and the specific phase of illness being targeted. Vraylar's preference for the dopamine D3 receptor and its long half-life are commonly cited reasons a psychiatrist may select it; its potential for early akathisia is a commonly cited reason for cautious titration. Long-half-life pharmacology means that assessment of clinical response unfolds over weeks, and the dose chosen at initiation may not be the dose at steady state.
For schizophrenia, Vraylar is taken once daily on an ongoing basis. For acute manic or mixed episodes of bipolar I, treatment is initiated during the episode and continued as the psychiatrist directs. For bipolar depression and adjunctive use in major depressive disorder, the goal is reduction of depressive symptoms in combination with the patient's existing treatment plan. The treating psychiatrist will review goals, monitoring, and the criteria for staying on therapy versus changing agents.
Patients on antipsychotic therapy generally need baseline and periodic monitoring, which may include weight and body-mass index, lipid panel, fasting glucose or HbA1c, blood pressure, and assessment for movement-related side effects. Continuity of monitoring is a reason patients sometimes prefer to stay with the specific brand and formulation their psychiatrist has selected, including when that brand is the US Vraylar and the patient is travelling, relocating, or living outside the US.
What is included in a Reserve Meds Vraylar case
A Reserve Meds case for Vraylar covers the full chain from intake to delivery. The named concierge coordinator confirms that the prescription, clinical justification, and patient identity documentation are complete before any procurement step begins. The regulatory team prepares country-specific named-patient or personal-import paperwork tailored to the destination, including translations where required. The procurement team places the order with a DSCSA-compliant US specialty wholesaler and confirms full serial-number traceability. The logistics team handles international shipping, customs documentation, and final-mile delivery, with proof-of-delivery returned to the case file. The coordinator remains the single point of contact for the patient and the treating psychiatrist throughout the case and across any refills the patient and psychiatrist subsequently arrange.
Start a request for Vraylar
Submit a 60-second intake. Our clinical team will reach out as our first cohort opens with case-specific feasibility, timeline, and a formal quote.
Reserved for you.